Theratechnologies Inc.

As of May 31, 2025, Theratechnologies Inc. has 45.98M shares outstanding.

These figures are as of May 31, 2025. The price-to-sales ratio is 1.54, and the price-to-book ratio stands at -2.28.

As of May 31, 2025, Theratechnologies Inc. trades at an EV/EBITDA multiple of 18.09 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.03 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Theratechnologies Inc. trades at an EV/FCF ratio of 6.09, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of May 31, 2025, Theratechnologies Inc. maintains a current ratio of 0.84, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -156.22, indicating conservative leverage, while an interest coverage ratio of 1.24 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended May 31, 2025. Return on assets (ROA) is negative at -14.85, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 755.15, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.70 indicates how many times Theratechnologies Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended May 31, 2025. That works out to an effective tax rate of 92.06, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended May 31, 2025, Theratechnologies Inc. posted a gross margin of 77.72, reflecting its pricing power and cost economics. The operating margin of 8.44 and net profit margin of -10.85 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2025. Free cash flow yield stands at 13.07, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 17.49, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Theratechnologies Inc. shareholders.

Theratechnologies Inc.'s most recent stock split took place on July 31, 2023 with a 4:1 split ratio.

As of May 31, 2025, Theratechnologies Inc. has an Altman Z-Score of -13.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.